I Agree

We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms of Use.

PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table

EMMAC Life Sciences

Pharmaceutical narcotics permits for Germany
RNS Number : 1169I
EMMAC Life Sciences Limited
31 March 2020
 

 

 

EMMAC Life Sciences Group

('EMMAC' or the 'Group')

 

EMMAC Secures Pharmaceutical Wholesaler and Narcotics Handling Permits for Germany

Immediate revenues from Europe's largest medical cannabis market

 

31 March 2020, London. EMMAC Life Sciences Group, Europe's leading independent cannabis company, is pleased to announce that its wholly owned subsidiary, About Nature Health GmbH ("About Nature"), has secured pharmaceutical wholesaler and narcotics handling permits for Germany, Europe's largest medical cannabis market.  The permits, granted according to section 52a AMG (German Pharmaceutical Law) and section 3 BMG (German Narcotics Law), will enable  EMMAC to drive immediate revenue growth in Germany with the sale of medical cannabis products.  EMMAC has a range of medical cannabis products, with different strengths and THC/CBD/CBG formulations in Oil and Flos1 formats, to address a wide range of specialist requirements.

 

According to the Bank of Montreal2, the German medical cannabis market could potentially produce more than US$5 billion in revenue for global cannabis producers, with an assumption that in seven years 7.5% of sleep, anxiety and pain prescriptions in Germany will be replaced with medical cannabis.

 

Antonio Costanzo, CEO of EMMAC, said: "The announcement today is an important milestone for EMMAC, and demonstrates the EU GDP compliant quality management systems About Nature has in place. EMMAC is now poised to deliver immediate revenues from Germany, and capitalise on the significant opportunities presented by the largest medical cannabis market in Europe, as we bring our products to market in 2020."

 

1   Dried female cannabis flower

2 https://business.financialpost.com/cannabis/cannabis-producers-could-be-chasing-global-market-worth-194-billion-in-seven-years-bmo-report  

 

 

- Ends -

 



 

About EMMAC Life Sciences Group

EMMAC Life Sciences Group is Europe's leading independent cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, EMMAC's vision is to bring the life-enhancing potential of cannabis to the people who need it.

 

 

Contact:

For scientific enquiries please contact research@emmac.com

For general enquiries please contact info@emmac.com or visit www.emmac.co m  

 

Media enquiries:

Buchanan


Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz

Tel: +44 (0) 20 7466 5000

emmac@buchanan.uk.com

www.buchanan.uk.com

 

CAUTIONARY STATEMENT

All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Group. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Group assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRASDLFISESSEID
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close